Chronic Lymphocytic Leukemia in Adults

Our oncologists, hematologists, and pathologists use advanced diagnostic tools and the latest treatments to manage chronic lymphocytic leukemia, a cancer of the blood and bone marrow that typically progresses slowly. Our specialists provide ongoing monitoring, care, and support to help you live with this chronic disease. We can also determine whether you can be monitored and delay treatment safely, or if you need to start tailored regimens of chemotherapy and newly approved targeted therapy to manage the condition.

Clinical Trials and Research Studies

Phase 1/2

AN OPEN-LABEL MULTICENTER PHASE l/1B TRIAL EVALUATING THE SAFETY ANDPHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT ANDCOMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORYB-CELL NON-HODGKIN S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA

Phase 2

AALL1521: INCB 18424-269 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia (ALL)

Phase 3

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

Phase 3

AALL1331; Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467 NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)